Filters

Term Search
You can select from the dropdown list OR enter your own terms to refine the search.

Last Updated: 10/31/2025

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 39 publications

The impact of surgery on patients with Von Hippel-Lindau-associated tumors: an international patient survey.

The impact of surgery on patients with Von Hippel-Lindau-associated tumors: an international patient survey.

Journal: The oncologist
Published: December 11, 2024

Belzutifan for von Hippel-Lindau disease-associated renal cell carcinoma and other neoplasms (LITESPARK-004): 50 months follow-up from a single-arm, phase 2 study.

Belzutifan for von Hippel-Lindau disease-associated renal cell carcinoma and other neoplasms (LITESPARK-004): 50 months follow-up from a single-arm, phase 2 study.

Journal: The Lancet. Oncology
Published: October 08, 2024

"Incidentally" discovered Von Hippel Lindau disease: an emerging clinical phenotype.

"Incidentally" discovered Von Hippel Lindau disease: an emerging clinical phenotype.

Journal: The oncologist
Published: July 06, 2024

MITF regulates IDH1, NNT, and a transcriptional program protecting melanoma from reactive oxygen species.

MITF regulates IDH1, NNT, and a transcriptional program protecting melanoma from reactive oxygen species.

Journal: Scientific reports
Published: March 26, 2024

Belzutifan for patients with von Hippel-Lindau disease-associated CNS haemangioblastomas (LITESPARK-004): a multicentre, single-arm, phase 2 study.

Belzutifan for patients with von Hippel-Lindau disease-associated CNS haemangioblastomas (LITESPARK-004): a multicentre, single-arm, phase 2 study.

Journal: The Lancet. Oncology
Published: December 18, 2023

MITF regulates IDH1 and NNT and drives a transcriptional program protecting cutaneous melanoma from reactive oxygen species.

MITF regulates IDH1 and NNT and drives a transcriptional program protecting cutaneous melanoma from reactive oxygen species.

Journal: bioRxiv : the preprint server for biology
Published: November 28, 2023

Belzutifan for von Hippel-Lindau Disease: Pancreatic Lesion Population of the Phase 2 LITESPARK-004 Study.

Belzutifan for von Hippel-Lindau Disease: Pancreatic Lesion Population of the Phase 2 LITESPARK-004 Study.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: August 30, 2023

Diseases of Hereditary Renal Cell Cancers.

Diseases of Hereditary Renal Cell Cancers.

Journal: The Urologic clinics of North America
Published: March 22, 2023

Understanding the Impact of Belzutifan on Treatment Strategies for Patients with VHL.

Understanding the Impact of Belzutifan on Treatment Strategies for Patients with VHL.

Journal: Journal of kidney cancer and VHL
Published: June 28, 2022

Seventh BHD international symposium: recent scientific and clinical advancement.

Seventh BHD international symposium: recent scientific and clinical advancement.

Journal: Oncotarget
Published: December 23, 2021

Belzutifan for Renal Cell Carcinoma in von Hippel-Lindau Disease.

Belzutifan for Renal Cell Carcinoma in von Hippel-Lindau Disease.

Journal: The New England journal of medicine
Published: November 24, 2021

Telaglenastat Plus Cabozantinib or Everolimus for Advanced or Metastatic Renal Cell Carcinoma: An Open-Label Phase I Trial.

Telaglenastat Plus Cabozantinib or Everolimus for Advanced or Metastatic Renal Cell Carcinoma: An Open-Label Phase I Trial.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: August 18, 2021
Showing 1-12 of 39

Last Updated: 10/31/2025